Phase II results of the first clinical trial of a tau aggregation inhibitor (TAI) for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.
The promises are coming home to roost for AstraZeneca CEO Pascal Soriot. Or so reports The Sunday Times, which says the U.K.-based company is once again under pressure to put Soriot's bonus pay on the line for the big goals he touted in defending against Pfizer's $100 billion takeover bid last year.
Cyfuse Biomedical is aiming to take its 3-D bioprinting technology to researchers around the world with its infusion of ¥1.4 billion ($12 million). Its bioprinter can be used to create tissue structures including cartilage and subchondral bone, tubular tissues such as blood vessels, digestive and urinary organs, and miniature livers.
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.
Months removed from a $150 million IPO, INC Research is looking to raise its profile among the world's largest CROs, inching toward the $1 billion annual revenue mark in the new year.
Bayer Healthcare said it plans to sell its animal health production facility in St. Joseph, MO, and some of the products manufactured at the plant.
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015.
Shares of generic drug maker Akorn ($AKRX) shot up 14% late last week to $55.86, after the company announced on Thursday strong preliminary 2014 results and expectations of 2015 year-over-year revenue growth of 47% and earnings-per-share growth of 62%.
Tax inversion deals are not the only trick Big Pharma has up its sleeve to avoid steep U.S. taxes. Gilead Sciences is booking profits overseas in low-tax countries to take home more profits for its blockbuster hep C drug Sovaldi.
It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.